These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1125 related items for PubMed ID: 11500850

  • 1. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R.
    Cytometry; 2001 Aug 01; 44(4):338-48. PubMed ID: 11500850
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
    Jackson JG, St Clair P, Sliwkowski MX, Brattain MG.
    Cancer Res; 2004 Apr 01; 64(7):2601-9. PubMed ID: 15059917
    [Abstract] [Full Text] [Related]

  • 7. Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells.
    Fiddes RJ, Janes PW, Sanderson GM, Sivertsen SP, Sutherland RL, Daly RJ.
    Cell Growth Differ; 1995 Dec 01; 6(12):1567-77. PubMed ID: 9019162
    [Abstract] [Full Text] [Related]

  • 8. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.
    Breast Cancer Res; 2007 Dec 01; 9(4):R50. PubMed ID: 17686159
    [Abstract] [Full Text] [Related]

  • 9. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
    Awasthi S, Hamburger AW.
    J Cell Physiol; 2014 Nov 01; 229(11):1831-41. PubMed ID: 24692179
    [Abstract] [Full Text] [Related]

  • 10. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
    Lewis GD, Lofgren JA, McMurtrey AE, Nuijens A, Fendly BM, Bauer KD, Sliwkowski MX.
    Cancer Res; 1996 Mar 15; 56(6):1457-65. PubMed ID: 8640840
    [Abstract] [Full Text] [Related]

  • 11. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
    Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH.
    EMBO J; 1997 Sep 15; 16(18):5608-17. PubMed ID: 9312020
    [Abstract] [Full Text] [Related]

  • 12. Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF.
    Deb TB, Su L, Wong L, Bonvini E, Wells A, David M, Johnson GR.
    J Biol Chem; 2001 May 04; 276(18):15554-60. PubMed ID: 11279155
    [Abstract] [Full Text] [Related]

  • 13. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
    Daly JM, Olayioye MA, Wong AM, Neve R, Lane HA, Maurer FG, Hynes NE.
    Oncogene; 1999 Jun 10; 18(23):3440-51. PubMed ID: 10376522
    [Abstract] [Full Text] [Related]

  • 14. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
    Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C, Edgerton SM, Yang X, Thor AD.
    Breast Cancer Res; 2005 Jun 10; 7(5):R708-18. PubMed ID: 16168116
    [Abstract] [Full Text] [Related]

  • 15. Presence of EGF growth factor ligands and their effects on cultured rat conjunctival goblet cell proliferation.
    Gu J, Chen L, Shatos MA, Rios JD, Gulati A, Hodges RR, Dartt DA.
    Exp Eye Res; 2008 Feb 10; 86(2):322-34. PubMed ID: 18155194
    [Abstract] [Full Text] [Related]

  • 16. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF.
    El Sheikh SS, Domin J, Abel P, Stamp G, Lalani el-N.
    Neoplasia; 2004 Feb 10; 6(6):846-53. PubMed ID: 15720812
    [Abstract] [Full Text] [Related]

  • 17. EGF-induced redistribution of erbB2 on breast tumor cells: flow and image cytometric energy transfer measurements.
    Nagy P, Bene L, Balázs M, Hyun WC, Lockett SJ, Chiang NY, Waldman F, Feuerstein BG, Damjanovich S, Szöllosi J.
    Cytometry; 1998 Jun 01; 32(2):120-31. PubMed ID: 9627225
    [Abstract] [Full Text] [Related]

  • 18. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, Kuwano M.
    Mol Cancer Ther; 2004 Apr 01; 3(4):465-72. PubMed ID: 15078990
    [Abstract] [Full Text] [Related]

  • 19. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration.
    Bourguignon LY, Gilad E, Peyrollier K.
    J Biol Chem; 2007 Jul 06; 282(27):19426-41. PubMed ID: 17493932
    [Abstract] [Full Text] [Related]

  • 20. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
    Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE.
    Proc Natl Acad Sci U S A; 2003 Jul 22; 100(15):8933-8. PubMed ID: 12853564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.